IL-23

Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Metanalysis of 10 studies shows reactivation in 21% of HBsAg+ patients without prophylaxis vs 4.4% in HBsAg−/HBcAb+ patients. https://t.co/eHzIeA8uJK https://t.co/CmZw8C8ibn

Links:

Dr. John Cush @RheumNow( View Tweet )
men and women

ICYMI: Sex related differences in PsA

Adela Castro, MD

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes

Read Article
RheumNow Podcast square

54K Peptic Ulcers Annually (12.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
Roundup cover

ACR24: Rheumatology Roundup

Jack Cush, MD

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article
men and women

Sex related differences in PsA

Adela Castro, MD

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes

Read Article
What is the effect of cs/bDMARDs on weight in #PsA? ⬇️Weight loss seen with: IL17i IL23i csDMARDs ⬆️Weight gain seen with: TNFi IL12/23i Important to consider #comorbidity & #BMI in management decisions in PsA Ab2639 #ACR24 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

A#2585 PsABIOnd observ cohort study of IL23 (GUS) or IL17i 6 mo interim results of 686 pts PROs: PsAID-12 High Rx persistence at 6mo -94% on both Rx Comparable improvement in PsAID-12 - best results skin, discomfort 1/2 with clinically meaningful improvement #ACR24 @RheumNow https://t.co/TM1jwTRR7C

Links:

Eric Dein @ericdeinmd( View Tweet )
A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m

Links:

Eric Dein @ericdeinmd( View Tweet )
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

Links:

Adela Castro @AdelaCastro222( View Tweet )
BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52. Supports addtl evidence of BKZ's winning streak in #axSpA @RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8

Links:

sheila @RHEUMarampa( View Tweet )
Exciting early data for new highly selective TYK2i zasocitinib Improved PASI skin scores (though not as much as IL23i...) Funky skin-related adverse events at higher doses, not sure what to make of that? #ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh

Links:

Mike Putman @EBRheum( View Tweet )
#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai 💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%) ⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai. 🔴Durable therapy ❓better outcomes #ACR @RheumNow https://t.co/LfA3WygNVq

Links:

Caoilfhionn Connolly @CaoilfhionnMD( View Tweet )
Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis Interesting as lots Of data On #enthesitis wIL23i Likely all Effective #PsA Rx helps #tenosynovitis some have ➡️ data on #efficacy ⬆️ bio rationale #ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj

Links:

Janet Pope @Janetbirdope( View Tweet )

Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
FDA's perspective on the use of artificial intelligence in drug development. - FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety - Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn
Dr. John Cush @RheumNow( View Tweet )
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

ANA+ consult (10.18.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Cytokines/biomarkers from IL-23/IL-17 pathways are Increased in psoriasis. Subanalysis of phase 2 254 pt PsO trial revealed that 12 wks of deucravacitinib assoc w/ reduction in IL-17A, IL-17C, beta-defensin, PI3 - decreases correlated w/ PASI changes https://t.co/Ii381B2mZx https://t.co/vXDyLUsKPi

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Dot the "i", Cross the "t" (10.11.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.

Read Article
RheumNow Podcast square

Stop Counting Bugs (10.4.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.

Read Article
UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article

Recent Blogs

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!  Read Post

Best of 2022: Toss of a Coin - How do You Choose PsA Medication?

M. Elaine Husni, MD, MPH
Coin toss
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they?  Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×